Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Tasly Acquires China Rights to Sutro ADC in $385 Million Agreement

publication date: Dec 27, 2021

Shanghai Tasly Pharma acquired Greater China rights to an antibody-drug conjugate from Sutro Biopharma of South San Francisco in a deal worth up to $385 million. Sutro is currently testing STRO-002, a FolRα-targeting ADC, in a Phase I test for ovarian and endometrial cancers in the US and Europe. Sutro will receive an upfront payment of $40 million and be eligible for $345 million in milestone payments. Tasly has the possibility of adding non-small cell lung cancer and triple-negative breast cancer indications. More details....

Stock Symbols: (SHA:600535) (NSDQ: STRO)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.